BioVie announced on November 3, 2026, that A.G.P./Alliance Global Partners has been retained as its exclusive placement agent to sell Class A common stock, pre-funded warrants, and common warrants under a 'best efforts' basis. This agreement facilitates capital raising efforts by the biotechnology company.